Important Topics: Myocardial Infarction NSAIDs Bronchial Asthma Adverse Drug Reactions (ADRs) Alzheimer’s Disease Opioid Analgesics Beta Blockers Congestive Heart Failure (CHF)

I need to clarify what you're looking for with these topics before diving in.

Asking for Preferences

What do you need for these topics? · What is your level / context?

Give me answer for this questions with reference to pharmacology exam for bpth student 7 marks

Reading File

Now let me search the medical library in parallel for all 8 topics.

Finding Sources

I now have enough from the library to compile detailed, exam-ready 7-mark answers. Here are all 8 topics written specifically for a BPT (Bachelor of Physiotherapy) Pharmacology exam:

Pharmacology - 7-Mark Exam Answers (BPT)

1. Myocardial Infarction (MI) - Pharmacological Management

Definition: MI is irreversible myocardial cell death due to prolonged ischemia, usually from coronary artery occlusion by a thrombus.

Pathophysiology (Briefly)

Atherosclerotic plaque rupture → platelet aggregation → thrombus → coronary occlusion → ischemia → necrosis.

Drug Treatment of Acute MI (MONA + others)

Drug	Purpose
Morphine	Relieves pain & reduces preload/anxiety
Oxygen	Corrects hypoxia
Nitrates (glyceryl trinitrate)	Vasodilation - reduces preload & pain
Aspirin (300 mg stat)	Antiplatelet - prevents further clot

Additional Drugs

1. Thrombolytics (Fibrinolytics)

Streptokinase, Alteplase (tPA)
Dissolve the thrombus; given within 12 hours if PCI unavailable
Mechanism: Convert plasminogen → plasmin → fibrin degradation

2. Antiplatelet Agents

Aspirin (irreversibly inhibits COX → reduces TXA2)
Clopidogrel (blocks ADP/P2Y12 receptor)
Used together (dual antiplatelet therapy)

3. Anticoagulants

Heparin (UFH / LMWH) - prevents thrombus extension
Enoxaparin preferred (subcutaneous, predictable)

4. Beta Blockers (e.g., Metoprolol, Atenolol)

Reduce heart rate, O2 demand, and arrhythmias
Started early, continued long-term
Reduce mortality post-MI

5. ACE Inhibitors (e.g., Ramipril, Lisinopril)

Prevent ventricular remodeling
Reduce mortality, especially with reduced ejection fraction

6. Statins (e.g., Atorvastatin)

Stabilize plaques, reduce LDL
Started early and continued lifelong

Relevance to BPT

Beta blockers and statins are continued long-term; physiotherapists must know exercise is limited in acute phase and gradually reintroduced in cardiac rehab.

References: Goldman-Cecil Medicine; Fuster & Hurst's The Heart, 15th Ed.; Katzung's Basic & Clinical Pharmacology, 16th Ed.

2. NSAIDs - Non-Steroidal Anti-Inflammatory Drugs

Definition: NSAIDs are drugs that reduce inflammation, pain, and fever by inhibiting cyclooxygenase (COX) enzymes.

Mechanism of Action

Inhibit COX-1 and COX-2 enzymes → reduce synthesis of prostaglandins & thromboxane
Prostaglandins sensitize pain receptors (peripheral sensitization) and cause fever via hypothalamic action
COX-1 - constitutive (gastric protection, platelet aggregation)
COX-2 - inducible (inflammation, pain, fever)

Classification

Type	Examples
Non-selective COX inhibitors	Ibuprofen, Diclofenac, Naproxen, Indomethacin
Selective COX-2 inhibitors	Celecoxib, Etoricoxib
Analgesic/antipyretic (weak anti-inflammatory)	Paracetamol (acetaminophen)

Pharmacological Actions

Analgesic - peripheral and some central action
Anti-inflammatory - reduce prostaglandin-mediated inflammation
Antipyretic - inhibit PGE2 in hypothalamus
Antiplatelet - Aspirin irreversibly inhibits platelet COX-1

Adverse Effects (Important for Exam)

System	Effect
GI	Peptic ulceration, GI bleeding (due to loss of COX-1 protective PGs)
Renal	Acute renal failure, fluid retention, hypertension
Cardiovascular	COX-2 inhibitors increase MI/stroke risk
Respiratory	Aspirin-induced asthma (in sensitive patients)
Haematological	Bleeding (platelet inhibition)
Pregnancy	Premature closure of ductus arteriosus; avoid in 3rd trimester

Uses in Physiotherapy Practice

Muscle pain, joint inflammation, post-operative pain
BPT relevance: NSAIDs are commonly used by physiotherapy patients; physiotherapists must counsel about GI protection and renal risk

Reference: Katzung's Basic & Clinical Pharmacology, 16th Ed.; Rheumatology, 2-Volume Set (Elsevier, 2022)

3. Bronchial Asthma - Pharmacological Management

Definition: Asthma is a chronic inflammatory disorder of airways characterized by reversible airway obstruction, bronchospasm, and airway hyperresponsiveness.

Pathophysiology (Brief)

Allergen/trigger → mast cell degranulation → release of histamine, leukotrienes, prostaglandins → bronchoconstriction + inflammation + mucus hypersecretion.

Drug Classification

A. Bronchodilators (Relievers)

1. Beta-2 Adrenergic Agonists

SABA (Short-Acting): Salbutamol (Albuterol) - reliever inhaler, onset 5 min
LABA (Long-Acting): Salmeterol, Formoterol - used with ICS
Mechanism: Activate β2 receptors → increase cAMP → relax bronchial smooth muscle

2. Anticholinergics (Ipratropium)

Block muscarinic receptors → reduce bronchoconstriction
More useful in COPD; useful in acute severe asthma

3. Methylxanthines (Theophylline)

Inhibit phosphodiesterase → increase cAMP
Narrow therapeutic index; monitor serum levels

B. Anti-Inflammatory Drugs (Controllers)

1. Inhaled Corticosteroids (ICS) - First-line controller

Beclomethasone, Budesonide, Fluticasone
Suppress airway inflammation, reduce cytokine production
Given by inhalation to minimize systemic effects

2. Systemic Corticosteroids

Prednisolone, IV Hydrocortisone
Used in acute severe asthma

3. Leukotriene Receptor Antagonists

Montelukast, Zafirlukast
Block LTD4 receptors → reduce bronchoconstriction and inflammation
Useful in aspirin-sensitive asthma

4. Mast Cell Stabilizers

Sodium cromoglicate - prevents mast cell degranulation
Prophylactic only, not for acute attacks

5. Monoclonal Antibodies (Biologics)

Omalizumab (anti-IgE) - severe allergic asthma

BPT Relevance

Breathing exercises, chest physiotherapy, and pulmonary rehabilitation complement drug therapy
Physiotherapists must know inhaler techniques and recognize an acute attack

References: Goodman & Gilman's Pharmacological Basis of Therapeutics; Cellular & Molecular Immunology; Scott-Brown's Otorhinolaryngology

4. Adverse Drug Reactions (ADRs)

Definition (WHO): "A response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease."

Classification (Rawlins & Thompson - Type A/B)

Type	Name	Description	Example
Type A	Augmented	Dose-dependent, predictable, pharmacological	Beta blocker - bradycardia
Type B	Bizarre	Dose-independent, unpredictable, idiosyncratic/allergic	Penicillin anaphylaxis
Type C	Chronic	Long-term use effects	Steroid osteoporosis
Type D	Delayed	Appear after long latency	Carcinogenesis, teratogenicity
Type E	End-of-use	Withdrawal reactions	Opioid withdrawal
Type F	Failure	Unexpected failure of therapy	Drug interaction reducing efficacy

Mechanisms of ADRs

Pharmacological (on-target): Drug acts on intended receptor excessively - e.g., hypoglycemia with insulin
Off-target effects: Drug acts on unintended receptor - e.g., antihistamine causing sedation
Immune-mediated (drug allergy):
- Type I (IgE-mediated): Anaphylaxis - penicillin, NSAIDs
- Type II (Cytotoxic): Hemolytic anemia - methyldopa
- Type III (Immune complex): Serum sickness
- Type IV (Cell-mediated): Contact dermatitis
Idiosyncratic: Genetically determined unusual response - e.g., G6PD deficiency causing hemolysis with primaquine
Teratogenic: Drug causes fetal malformation - thalidomide

Factors Predisposing to ADRs

Age (elderly, neonates)
Renal/hepatic disease (impaired drug elimination)
Polypharmacy
Genetic factors (pharmacogenomics)
Previous allergic history

Monitoring and Reporting

Pharmacovigilance programs (Yellow Card in UK; PvPI in India)
Causality assessment: WHO-UMC scale, Naranjo Algorithm

References: Goldman-Cecil Medicine; Katzung's Basic & Clinical Pharmacology, 16th Ed.; Murray & Nadel's Respiratory Medicine

5. Alzheimer's Disease - Pharmacological Management

Definition: Alzheimer's disease (AD) is the most common neurodegenerative cause of dementia, characterized by progressive cognitive decline, memory loss, and behavioral changes.

Pathophysiology

Cholinergic hypothesis: Loss of cholinergic neurons in nucleus basalis of Meynert → reduced ACh in cortex/hippocampus
Amyloid hypothesis: Accumulation of β-amyloid plaques (senile plaques)
Tau hypothesis: Neurofibrillary tangles from hyperphosphorylated tau protein

Drug Treatment

A. Cholinesterase Inhibitors (ChEIs) - First-line

Mechanism: Inhibit acetylcholinesterase (AChE) → increased ACh in synaptic cleft → improved cholinergic transmission

Drug	Generation	Dose Form
Donepezil (Aricept)	2nd gen	Oral, once daily
Rivastigmine (Exelon)	2nd gen	Oral + Transdermal patch
Galantamine (Razadyne)	2nd gen	Oral, also allosteric nicotinic modulator
Tacrine	1st gen	Hepatotoxic, rarely used

Approved for mild to moderate AD (Donepezil also for severe AD)
Adverse effects: Nausea, vomiting, diarrhea, bradycardia (cholinergic)

B. NMDA Receptor Antagonist

Memantine (Namenda)
Mechanism: Non-competitive antagonist of NMDA receptors → reduces excitotoxicity from excess glutamate
Approved for moderate to severe AD
Can be combined with ChEIs
Adverse effects: Dizziness, confusion, headache

C. Novel/Emerging Therapies (Recent)

Lecanemab, Aducanumab - anti-amyloid monoclonal antibodies (FDA-approved 2023)
Aim to slow disease progression

D. Symptomatic Management

Antidepressants (SSRIs for behavioral symptoms)
Antipsychotics (for agitation - use cautiously, increased mortality risk in elderly)

BPT Relevance

Physiotherapists working in neurorehabilitation must understand cognitive impairment, medication side effects (e.g., falls risk with sedating drugs)
Exercise therapy shown to slow cognitive decline

References: Kaplan & Sadock's Comprehensive Textbook of Psychiatry; The Maudsley Prescribing Guidelines

6. Opioid Analgesics

Definition: Opioids are drugs that act on opioid receptors (μ, κ, δ) to produce analgesia and other CNS effects.

Opioid Receptors

Receptor	Effects
μ (Mu)	Supraspinal analgesia, euphoria, respiratory depression, dependence
κ (Kappa)	Spinal analgesia, sedation, dysphoria
δ (Delta)	Analgesia, modulation of μ-receptor activity

Mechanism of Action

Activate Gi-coupled opioid receptors → decrease cAMP → hyperpolarize neurons (increase K+ outflow, decrease Ca2+ influx) → reduce pain signal transmission.

Classification

Class	Examples
Strong opioids	Morphine, Fentanyl, Oxycodone, Methadone
Moderate opioids	Codeine, Tramadol, Buprenorphine
Weak opioids	-
Antagonists	Naloxone, Naltrexone
Mixed agonist-antagonists	Pentazocine, Buprenorphine

Pharmacological Effects of Morphine

CNS: Analgesia, euphoria, sedation, respiratory depression, cough suppression, miosis (pupil constriction)
CVS: Vasodilation, hypotension (histamine release)
GI: Constipation (decreased gut motility), nausea/vomiting
Urinary: Urinary retention (increased sphincter tone)
Uterus: May prolong labor

Adverse Effects

Respiratory depression (most dangerous; treat with Naloxone)
Constipation
Tolerance and dependence
Nausea/vomiting
Sedation, confusion
Miosis

Codeine

Prodrug - converted to morphine in liver by CYP2D6
Analgesic and antitussive use

Tramadol

Weak opioid + inhibits serotonin & noradrenaline reuptake
Lower abuse potential, less respiratory depression

Clinical Uses

Severe acute pain (post-operative, trauma)
Chronic cancer pain (WHO pain ladder - Step 3)
MI pain (morphine IV)
Cough (codeine, pholcodine)
Diarrhea (loperamide)
Palliative care

BPT Relevance

Pain management in physiotherapy patients - understanding when opioids are used
Constipation and sedation are important to consider in mobilization plans

References: Katzung's Basic & Clinical Pharmacology, 16th Ed.; Goodman & Gilman's Pharmacological Basis of Therapeutics

7. Beta Blockers (Beta-Adrenergic Blocking Agents)

Definition: Beta blockers are drugs that competitively block β-adrenergic receptors, thereby inhibiting the effects of catecholamines (adrenaline, noradrenaline).

Classification

Class	Examples	Feature
Non-selective (β1 + β2)	Propranolol, Nadolol	Block both β1 and β2
Cardioselective (β1)	Atenolol, Metoprolol, Bisoprolol	Prefer β1 at cardiac level
With ISA	Pindolol, Acebutolol	Partial agonist activity
With vasodilating property	Carvedilol (α+β), Labetalol (α+β)	Block α1 also

Mechanism of Action

Block β1 receptors in heart → decrease:

Heart rate (negative chronotropy)
Force of contraction (negative inotropy)
Cardiac output
Renin release from kidney (anti-hypertensive)

Block β2 receptors (non-selective) → bronchoconstriction (AVOID in asthma)

Pharmacological Effects

Heart - Reduced HR, contractility, conduction velocity (at AV node)
Blood Pressure - Decreased (reduce CO + renin)
Kidneys - Reduced renin secretion
Lungs - Bronchoconstriction (β2 blockade - non-selective drugs)
Metabolic - Mask hypoglycemia symptoms; reduce lipolysis

Clinical Uses

Hypertension - especially with tachycardia, anxiety
Angina pectoris - reduce O2 demand
Myocardial Infarction - reduce mortality, arrhythmias
Heart Failure - Carvedilol, Metoprolol, Bisoprolol (paradoxical benefit - counteract sympathetic overactivation)
Arrhythmias - SVT, AF rate control
Thyrotoxicosis - control tachycardia symptoms
Migraine prophylaxis - Propranolol
Glaucoma - Timolol (eye drops)
Anxiety/Tremor - Propranolol (performance anxiety)

Adverse Effects

Effect	Cause
Bradycardia, heart block	β1 blockade
Bronchoconstriction	β2 blockade
Cold extremities	Peripheral vasoconstriction
Fatigue, depression	CNS effects
Masking hypoglycemia	β2 blockade
Impotence

Contraindications

Asthma / COPD (non-selective)
AV block (>1st degree)
Cardiogenic shock
Avoid abrupt withdrawal (rebound angina, MI)

BPT Relevance

Patients on beta blockers have blunted heart rate response to exercise - use RPE (Borg scale) instead of heart rate targets during exercise prescription

References: Katzung's Basic & Clinical Pharmacology, 16th Ed.; Goodman & Gilman's Pharmacological Basis of Therapeutics; Rosen's Emergency Medicine

8. Congestive Heart Failure (CHF) - Pharmacological Management

Definition: CHF is a clinical syndrome where the heart fails to pump sufficient blood to meet the body's metabolic needs, or does so only at elevated filling pressures.

Pathophysiology (Brief)

Reduced cardiac output → compensatory mechanisms (SNS activation, RAAS activation, ADH release) → initially helpful but long-term harmful → cardiac remodeling → worsening failure.

Goals of Treatment

Relieve symptoms (reduce fluid overload)
Slow disease progression
Reduce mortality

Drug Treatment

A. Diuretics (Symptom Relief)

Loop diuretics: Furosemide (Frusemide) - most potent; block Na-K-2Cl in loop of Henle → reduce fluid overload
Thiazides: Hydrochlorothiazide - milder; block NaCl in DCT
Potassium-sparing: Spironolactone (aldosterone antagonist) - also reduces cardiac remodeling

B. ACE Inhibitors (Reduce Mortality - First-line)

Ramipril, Enalapril, Lisinopril
Block conversion of Angiotensin I → II → reduce vasoconstriction, reduce aldosterone
Reduce preload + afterload, prevent remodeling
Reduce mortality by 20-25%
ADR: Dry cough, hyperkalemia, angioedema

C. ARBs (if ACE inhibitor intolerant)

Losartan, Valsartan, Candesartan
Block AT1 receptors directly
No cough (advantage over ACEi)

D. Beta Blockers (Reduce Mortality)

Carvedilol, Metoprolol succinate, Bisoprolol
Counteract harmful sympathetic activation
Improve ejection fraction over time
Start low, titrate slowly - can worsen acute failure initially

E. Cardiac Glycosides

Digoxin - inhibits Na/K ATPase pump → increased intracellular Na → increased Ca → increased contractility (positive inotropy)
Reduces symptoms and hospitalization; NO mortality benefit
Also slows HR (AV node blockade via vagal stimulation)
Narrow therapeutic index - monitor levels; toxicity: nausea, yellow vision, arrhythmias

F. Aldosterone Antagonists

Spironolactone, Eplerenone
Reduce cardiac fibrosis and remodeling
Reduce mortality in systolic HF

G. ARNI (Angiotensin Receptor Neprilysin Inhibitor)

Sacubitril/Valsartan (Entresto)
Newer drug; superior to ACEi in reducing mortality
First-line in HFrEF guidelines

H. SGLT2 Inhibitors

Dapagliflozin, Empagliflozin
Originally antidiabetic; proven to reduce HF hospitalizations and mortality
Now guideline-recommended for HFrEF regardless of diabetes

I. Vasodilators

Nitrates + Hydralazine: reduce preload and afterload
Used when ACEi/ARBs not tolerated

BPT Relevance

Cardiac rehabilitation - graded exercise is a proven adjunct
Patients on loop diuretics need monitoring for electrolyte imbalance (hypokalemia - increases fall/cramp risk)
Digoxin toxicity monitoring important

References: Goldman-Cecil Medicine; Harrison's Principles of Internal Medicine, 22nd Ed. (2025); Fuster & Hurst's The Heart, 15th Ed.; Katzung's Basic & Clinical Pharmacology, 16th Ed.

Quick Summary Table for Revision

Topic	Key Drug Classes	Key Mechanism
MI	Aspirin, Thrombolytics, ACEi, Beta blockers, Statins	Reperfusion, prevent remodeling
NSAIDs	Ibuprofen, Celecoxib, Aspirin	COX inhibition → reduce PGs
Asthma	Salbutamol (SABA), ICS, Montelukast	Bronchodilation + anti-inflammation
ADRs	Classification: Type A-F	Dose-related vs Unpredictable
Alzheimer's	Donepezil, Memantine	ChEI + NMDA antagonist
Opioids	Morphine, Codeine, Tramadol	μ/κ/δ receptor agonism
Beta Blockers	Propranolol, Atenolol, Carvedilol	β receptor blockade
CHF	Furosemide, ACEi, Digoxin, ARNI	Reduce preload/afterload, improve contractility

---All 8 topics are covered above with complete 7-mark exam-ready answers tailored for BPT pharmacology. Here are some exam tips:

How to write a 7-mark answer:

Definition (0.5 mark)
Classification or Mechanism (1-2 marks)
Pharmacological effects / Actions (1-2 marks)
Adverse effects (1 mark)
Clinical Uses (1 mark)
BPT Relevance (bonus - shows clinical application)

Most important topics to focus on for BPT exams:

Beta Blockers - blunted heart rate during exercise is directly relevant to your practice
NSAIDs - most commonly used in musculoskeletal patients
Bronchial Asthma - inhaler techniques and breathing exercises are core BPT skills
Opioids - pain management after surgery/trauma relevant to post-op rehab
CHF - cardiac rehab is a major BPT domain

This is a shared conversation. Sign in to Orris to start your own chat.